New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Inclusion Criteria

• •Antiretroviral therapy (ART) experienced and currently receiving a stable regimen containing 3 nucleoside reverse transcriptase inhibitors (NRTIs), or 2 NRTIs plus a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) for at least 3 months (there should be no significant ART modifications for at least 3 months and no ART change anticipated between Screening and initiation of the study therapy).
• •Patients must be naive to tenofovir.
• •HIV-1 RNA level \> 1000 copies/ml on at least one occasion within 21 days of study entry.
• •A CD4 cell count \> 50 cells/mm3.
• •Specified viral genotypes.